Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro

International Immunopharmacology

Volumn 1, Issue 4, 2001, Pages 749-757

  Sakuma, Shozo ^a   Kato, Yasuko ^a   Nishigaki, Fusako ^a   Magari, Katsue ^a   Miyata, Susumu ^a   Ohkubo, Yoshitaka ^a   Goto, Toshio ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Cyclosporin A; Dexamethasone; FK506; IgM; IL 6; Methotrexate; Rheumatoid arthritis; T cells

Indexed keywords

AUTOANTIBODY; CD28 ANTIGEN; CD3 ANTIGEN; CYCLOSPORIN A; CYTOKINE; DEXAMETHASONE; IMMUNOGLOBULIN M; INTERLEUKIN 6; METHOTREXATE; TACROLIMUS;

ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, CD28; ANTIGENS, CD3; HUMANS; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; METHOTREXATE; T-LYMPHOCYTES; TACROLIMUS;

EID: 0035108541     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(01)00008-X     Document Type: Article

References (43)

1. FK506, a novel immunosuppressant isolated from streptomyces: II. Immunosuppressive effect of FK506 in vitro
2. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation
3. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes
4. Efficacy of FK506 in rheumatoid arthritis (RA): A 6 month, dose-ranging study in RA patients failing methotrexate (MTX)
5. FK506 potently inhibits TNF-α and IL-1β production in vitro by human peripheral blood mononuclear cells
6. Anti-cytokine therapy in rheumatoid arthritis
7. Biologic agents for treating rheumatoid arthritis. Concepts and progress
8. Induction of proliferation and Ig production in human B leukemic cells by anti-immunoglobulins and T cell factors
9. Interleukin-6 and its receptor in autoimmunity
10. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides
11. Interleukin 6 levels in synovial fluids of patients with different arthritides: Correlation with local IgM rheumatoid factor and systemic acute phase protein production
12. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis
13. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody
14. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody
15. Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: What have we learnt?
16. FK506 attenuates developing and established joint inflammation and suppresses interleukin 6 and nitric oxide expression in bacterial cell wall induced polyarthritis
17. FK506, an immunosuppresant, partially inhibits interleukin 6 production by adherent rheumatoid synovial cells
18. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level
19. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis
20. Effects of novel immunosuppressive agent, FK506, on human B cell activation
21. The effects of immunosuppressive agents on in vitro production of human immunoglobulins
22. The effect of methotrexate on in vitro immunoglobulin production
23. T cell-replacing factor for glucocorticoid-induced immunoglobulin production
24. Independent regulation of B-cell inducing factor and IL-2 production by T lymphocytes, and direct and indirect promotion of immunoglobulin secretion by glucocorticoid
25. Anti-inflammatory actions of glucocorticoids: Molecular mechanisms
26. Divergent activities of protein kinases in IL-6-induced differentiation of a human B cell line
27. Interleukin 6-induced differentiation of human B cell line into IgM-secreting plasma cells is mediated by c-fos
28. Brequinar sodium inhibits interleukin-6-induced differentiation of a human B-cell line into IgM-secreting plasma cells
29. SKW 6.4 cell differentiation induced by interleukin 6 is stimulated by butyrate
30. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to induce immunoglobulin
31. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells
32. Cytokine production in whole blood ex vivo
33. Auranofin inhibits the induction of interleukin 1β and tumor necrosis factor α mRNA in macrophages
34. The effects of antiinflammatory and antiallergic drugs on cytokine release after stimulation of human whole blood by lipopolysaccharide and zymosan A
35. Glucocorticoid modulation of human monocyte/macrophage function: Control of TNF-α secretion
36. Human interleukin 6 and tumor necrosis factor α production at a single-cell level
37. The direct effect of FK506 and rapamycin on interleukin 1(β) and immunoglobulin production in vitro
38. Antifolate analogs: Mechanism of action, analytical methodology, and clinical efficacy
39. Effect of methotrexate on murine bone marrow cells in vitro: Evidence of a reversible antiproliferative action
40. Molecular therapeutics. Methotrexate and its mechanism of action
41. Immunologic studies of rheumatoid arthritis patients treated with methotrexate
42. Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression
43. Therapeutic drug monitoring of tacrolimus in liver transplantation, phase III FK506 multicenter Spanish study group: A two-year follow-up